Nanjing Simcere Pharma has formed a collaboration to develop novel antiviral drugs for COVID-19 with the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences. Specifically, Simcere has exclusive global rights to develop and commercialize a small-molecule antiviral that targets the 3C-like protease, a key enzyme in the replication and of coronaviruses. In preclinical animal models, SIM0417 showed good antiviral activity and safety against SARS-CoV-2. The two entities will work together to promote clinical research and marketing of the candidate. More details.... Stock Symbol: (HK: 2096) Share this with colleagues: // //